How much will Foundayo cost in the UK?

What we know right now

Foundayo (orforglipron) was approved by the MHRA on 10 August 2026, the first once-daily GLP-1 tablet with no fasting rules, covered in detail in our launch guide. It launched in the UK later that month, Eli Lilly's first European market for the medicine, and UK pricing is now confirmed rather than the open question this page originally covered. This page has been updated to reflect the confirmed figures.

How much Foundayo costs a month

Eli Lilly's own guidance points to a private prescription price of roughly £100 to £120 a month. In practice, what patients are quoted varies by provider and by dose: many private online pharmacies list Foundayo from around £129 a month at the lower starting doses used during titration, rising to around £179 a month at the higher maintenance doses. As with the injectable GLP-1 medicines, providers set their own retail price on top of Lilly's supply cost, so the exact figure you are quoted can differ between pharmacies even at the same dose, and prices may continue to move as the market settles.

Foundayo is supplied across six dose strengths, and cost typically increases as your dose is titrated upward over the first weeks and months of treatment, in the same way the injectable pens become more expensive at higher doses. Ask any provider for the all-in monthly figure at your specific dose, including the consultation, rather than comparing headline "from" prices, which usually reflect the lowest starting dose only.

List prices, net prices and why both matter

Medicine pricing in the UK usually involves two numbers: a public list price, and confidential arrangements that determine what large purchasers actually pay. For patients, the list price shapes private prescription costs; for the NHS, the confidential net price is what NICE weighs against the medicine's benefits in deciding whether it is cost-effective. This is why a medicine can be judged too expensive for routine NHS use at one point and approved later after commercial negotiation, and why the NICE date in November matters commercially as well as clinically for Foundayo.

For budget-conscious readers, the practical takeaway still holds: do not defer the eligibility conversation. Consultations, medical history checks and treatment decisions take days, and a clinical consultation costs nothing to start, whatever the final monthly figure turns out to be for your dose and provider.

How the price compares with the injectables

Now that a number exists, the comparison is straightforward rather than speculative. Foundayo's confirmed private pricing, roughly £100 to £180 a month depending on dose and provider, sits within the same general range that private patients already pay for Mounjaro and Wegovy, which typically run in the low-to-mid hundreds of pounds per month depending on dose. The tablet has not produced an obvious price advantage over the injectables; where it launched relative to them turned out to be broadly level rather than a clear undercut or a clear premium.

That means the choice between Foundayo and an injectable is, for most people, less about price and more about preference: whether you would rather take a tablet every day or an injection once a week. Nothing about your eligibility changes based on which you choose: the consultation that qualifies you for one licensed treatment qualifies you to discuss all of them.

Tablet economics beyond the sticker price

A daily tablet also shifts small costs the sticker never shows. There is no sharps bin to arrange, no cold-chain delivery to be home for, no travel letters or cool bags for holidays, and a missed dose costs a day rather than disrupting a weekly cycle. Against that, daily adherence asks more of your routine than a weekly injection does, and treatment that is not taken consistently is the most expensive kind of all: money spent for diminished results. Factor your own habits honestly; they are part of the price.

Is Foundayo available on the NHS?

Not yet. NICE's appraisal committee met on 14 July 2026, and final guidance is due 18 November 2026; routine NHS funding depends on that outcome, which itself turns on the confidential price the NHS would pay. Until a recommendation is published and rollout follows, Foundayo remains a private-prescription medicine, accessed through regulated pharmacies after a clinician consultation, exactly like the injectable treatments today. Our guide to NHS eligibility explains how that system works for this class.

One variable specific to tablets is worth flagging: Foundayo is sold across six dose strengths, and a daily tablet's pricing structure (per pack, per dose tier, whether titration packs differ from maintenance packs) has its own geometry that affects monthly cost as your dose changes, distinct from how injectables price per pen at a given strength. Ask your provider to confirm the monthly cost at each stage of titration, not just the starting price.

What the first weeks after launch have looked like

New weight-management medicines have tended to launch into strong early demand with constrained stock in the UK, with early private access concentrated among providers who secured supply, before prices and availability settle as manufacturing scales up. Wegovy and Mounjaro both followed versions of this pattern. Foundayo's UK launch is still recent, so some early friction around stock and appointment availability at individual providers would not be unusual; this is normal launch mechanics rather than a reason to consider using an unregulated source, which will predictably try to exploit any gap.

A brief timeline recap for orientation: MHRA approval on 10 August 2026; UK launch later that month; private pricing confirmed at launch; NICE appraisal committee met 14 July 2026 with final guidance due 18 November 2026; NHS availability contingent on that outcome. Our launch guide covers the clinical detail; this page tracks the money.

How to think about value now the price is known

With a confirmed figure, compare it the way we recommend for any weight-loss treatment price: the all-in monthly cost at your dose, including consultations and delivery, over a realistic treatment duration, rather than a single headline number. A tablet adds its own considerations (no injection training, easier travel, a daily rather than weekly routine) which some people will value highly and others will not. Convenience is worth paying for only if it is convenience you will actually use.

If you want to start on a licensed option now that pricing is confirmed, a free consultation with a UK-registered clinician establishes eligibility that carries across whichever medicine ends up right for you. Our weight-management guides cover the whole landscape.